Juno Therapeutics (JUNO) Misses Q3 EPS by 2c

Juno Therapeutics (NASDAQ: JUNO) reported Q3 EPS of ($0.57), $0.02 worse than the analyst estimate of ($0.55). Revenue for the quarter came in at $20.8 million versus the consensus estimate of $10.63 million.

Cash, cash equivalents, and marketable securities as of September 30, 2016 were $1.04 billion compared to $1.11 billion as of June 30, 2016 and $1.22 billion as of December 31, 2015.

Juno Therapeutics reaffirmed FY2016 guidance.

For earnings history and earnings-related data on Juno Therapeutics (JUNO) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Zeo Energy Corp (ZEO) Misses Q2 EPS by 7c
• HeartCore Enterprises, Inc. (HTCR) Misses Q2 EPS by 185c